Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumor after failure with imatinib and sunitinib treatment

A meta-analysis

Zhenan Zhang, MMa, Tao Jiang, MDa, Wensheng Wang, BSb, Daxun Piao, MDa,*

Abstract

Aims: This meta-analysis aimed to evaluate the safety and efficacy of regorafenib as a treatment for patients with advanced (metastatic and/or unresectable) gastrointestinal stromal tumor (AGIST) after developing resistance to imatinib and sunitinib.

Methods: A literature search of databases such as PubMed, Embase, and Cochrane library was conducted up to February 2017. The pooled percentages and the corresponding 95% confidence intervals (CIs) were calculated using the Stata 11.0 software.

Results: Four studies involving 243 patients with AGIST were included. Results revealed that approximately 49% (95% CI 30–67), 14% (95% CI 5–23), and 41% (95% CI 21–61) of patients with AGIST showed clinical benefit (including complete response), partial response, and stable disease, respectively, after regorafenib treatment, which was given after failure with imatinib and sunitinib treatments. No complete response was found in the included studies. Pooled progression-free survival was 6.58 months (95% CI 4.62–8.54). Hypertension (20%; 95% CI 7–33), hand-foot skin reaction (22%; 95% CI 17–27), and hypophosphatemia (18%; 95% CI 5–41) were common grade ≥3 regorafenib-related adverse events in patients treated with regorafenib after failure with imatinib and sunitinib treatments.

Conclusions: Forty-nine per cent of patients with AGIST benefited after regorafenib treatment after the development of resistance to imatinib and sunitinib. More studies should be performed to improve the clinical survival of patients with AGIST. Close monitoring and appropriate management of grade ≥3 regorafenib-related adverse events should be considered during treatment.

Abbreviations: AGIST = advanced (metastatic and/or unresectable) gastrointestinal stromal tumor, CB = clinical benefit, CBR = clinical benefit rate, CIs = confidence intervals, CR = complete response, GIST = gastrointestinal stromal tumor, PFS = progression-free survival, PR = partial response, PRR = partial response rate, SD = stable disease, SDR = stable disease rate, VEGF = vascular endothelial growth factor.

Keywords: gastrointestinal stromal tumor, meta-analysis, regorafenib, tyrosine kinase inhibitor

1. Introduction

In the digestive tract, the most common mesenchymal tumor is the gastrointestinal stromal tumor (GIST), which most commonly arises in a gastric location (40%–60%) as a primary disease, with the 2 next most common sites being the small intestine and colon. Previous studies found that approximately 80% to 85% of GIST cases have mutations in the oncogene receptor tyrosine kinase (KIT) or Platelet-derived growth factor alpha receptor (PDGFRα).[1–4] The small molecule imatinib, a tyrosine kinase inhibitor against PDGFRα and KIT, has been approved for treating metastatic or unresectable GIST yearly.[1,2] However, delayed resistance to imatinib ultimately develops in the majority of patients with advanced GIST (AGIST), which is mostly caused by secondary mutations in the PDGFRα or KIT gene.[3,4] Then, sunitinib, another inhibitor of PDGFRα and KIT, is used as a second-line therapy after developing resistance to imatinib and has shown clinically meaningful efficacy in phase I to III trials.[5–7] However, drug resistance to sunitinib can also subsequently develop, generally within 1 year of treatment, but there is no proven efficient therapy after failure with imatinib and sunitinib treatment.[8,9]

Many studies have been currently performed to identify effective drugs for treating GISTs after failure with imatinib and sunitinib treatment.[10–12] Among these drugs, regorafenib is an oral multikinase inhibitor, which can block the activity of multiple protein kinases (including KIT, PDGFRα, and other related proteins).[13] Many studies have proved that regorafenib is effective for treating AGISTS after failure with imatinib and sunitinib treatment.[14–17] However, because of the limited sample size in individual studies and the controversial results, no definite
conclusion has been made regarding its effectiveness. Thus, we performed this meta-analysis to evaluate the safety and efficacy of regorafenib for treating patients with (metastatic/unresectable) AGIST who were resistant to imatinib and sunitinib.

2. Materials and methods

The methods used for this meta-analysis and generation of inclusion criteria were based on preferred reporting items for systematic review and meta-analysis recommendations. A statement of patient consent or the approval of ethics committee is not provided in our manuscript, as it is not relevant for a meta-analysis.

2.1. Literature search strategy

Databases such as PubMed, Embase, and Cochrane library were used for the literature search up to February 2017, using the following keywords: (“gastrointestinal stromal tumor” OR “GIST”) AND (“stivarga” OR “regorafenib” OR “second-generation tyrosine kinase inhibitor”). In addition, the references of relevant reviews were searched for additional studies.

2.2. Inclusion and exclusion criteria

The inclusion criteria were as follows: (1) subjects were patients with metastatic/unresectable GISTs and were aged >18 years; (2) regorafenib was used as a treatment after failure with imatinib and sunitinib treatment; and (3) clinical outcomes included at least 1 of the following outcomes: complete response (CR), partial response (PR), stable disease (SD), progression-free survival (PFS), grade ≥3 treatment-related toxicity, and clinical benefit (CB; defined as the proportion of patients with a clinical outcome of CR, PR, or SD).

The exclusion criteria were: (1) duplicated publications; or (2) reviews, letters, or comments. Only articles with full-text access were included.

2.3. Data extraction

The following data were recorded in a predesigned form: first author name, country, publication year, recruitment time, follow-up duration, sample size, age, sex, treatment, and outcome. Data extraction was independently performed by 2 investigators. Differences were resolved by discussion to ensure consistent evaluation.

2.4. Statistical analysis

The Stata 11.0 software was used for this meta-analysis. The I^2 and Cochran Q tests were used to assess heterogeneity among the included studies, with P values of <.1 or I^2 values of ≥50% being considered to be significant. An appropriate statistical model (fixed or random-effects model) was used to pool the percentages and corresponding 95% confidence intervals (CIs) based on the results of the heterogeneity test. For all of these analyses, P values <.05 indicated statistical significance.

3. Results

3.1. Characteristics of the included studies

After an initial literature search, 283 articles (PubMed, n = 121; Embase, n = 122; Cochrane library, n = 40) were identified. After excluding duplicates, 222 potentially relevant articles remained. Of these, 211 articles irrelevant studies were excluded by scanning the titles or abstracts, whereas 7 articles were excluded after reading the complete text. Finally, 4 studies[17,19–21] were included in this meta-analysis (Fig. 1).

The 4 studies involving 243 patients with GISTs were reanalyzed in this meta-analysis. The publication year ranged from 2013 to 2016. The recruitment time was between 2010 and 2014. The follow-up durations varied among these studies (from 12 to 44.9 months; Table 1).

Table 1

| Study | Year | Country | Recruitment time | Design | Follow up time, mos | Sample size | M/F | Age, y | Outcomes |
|-------|------|---------|------------------|--------|---------------------|-------------|-----|--------|----------|
| Ben-Ami et al[17] | 2016 | USA | February 2010 to January 2014 | Cohort | 41 (3.2–44.9) | 33 | 19/14 | 56 (25–76) | CB, PR, SD, PFS, grade ≥3 treatment-related toxicity |
| Son et al[19] | 2016 | Korea | December 2012 to December 2013 | Cohort | 12.7 (0.2–27.6) | 57 | 34/23 | 56 (50–62) | CB, SD, PFS, grade ≥3 treatment-related toxicity |
| Kollár et al[17] | 2014 | UK | March 2013 to September 2013 | Cohort | 12.6 | 20 | 13/7 | 68 (45–87) | CB, PR, SD, PFS, grade ≥3 treatment-related toxicity |
| Demetri et al[20] | 2013 | Multicenter | January 2011 to August 2011 | RCT | 12 | 133 | 85/48 | 60 (18–82) | CB, SD, PFS, grade ≥3 treatment-related toxicity |

CB = clinical benefit, F = female, M = male, NA = not available, PFS = progression-free survival, PR = partial response, RCT = randomized controlled trial, SD = stable disease.
3.2. Meta-analysis regarding the efficacy of regorafenib

In the 4 included studies, no patients attained CR after regorafenib treatment. However, the rates of PR, SD, and CB were reported and reanalyzed in this meta-analysis. Among the studies, significant heterogeneity ($I^2 > 50\%$; $P < .001$) was observed for the CB rate (CBR) and SD rate (SDR) (Fig. 2); thus, the random-effects model was used for pooling data. Furthermore, among the studies, no significant heterogeneity ($I^2 = 0\%$; $P = .389$) was observed for the PR rate (PRR); hence, the fixed-effects model was used. The pooled estimate indicated that approximately 49% (95% CI 30–67; Fig. 2A), 14% (95% CI 5–23; Fig. 2B), and 41% (95% CI 21–61; Fig. 2C) of patients with AGISTs attained CB, PR, and SD, respectively, after regorafenib treatment, which was given after failure with imatinib and sunitinib treatments.

Progression-free survival was determined for all 5 studies, and significant heterogeneity ($I^2 = 86.1\%$; $P < .001$) was observed among the studies. This meta-analysis revealed that the pooled PFS was 6.58 months (95% CI 4.62–8.54; Fig. 2D) in patients after regorafenib treatment, which was given after failure with imatinib and sunitinib treatments.

3.3. Meta-analysis regarding the safety of regorafenib

Table 2 shows the results for grade $\geq 3$ regorafenib-related adverse events. Among the studies, significant heterogeneity ($I^2 = 83.9\%$; $P < .001$) was observed only in the analysis of hypertension; thus, the random-effects model should be used. Nevertheless, the fixed-effects model should be used for pooling other adverse events owing to the lack of significant heterogeneity ($I^2 < 50\%$; $P > .1$). Pooled data showed that the incidences of hypertension, hand–foot skin reaction, and hypophosphatemia were 20% (95% CI 7–33), 22% (95% CI 17–27), and 18% (95% CI 5–31), respectively, indicating that they were common adverse events. In addition, approximately 6%, 3%, and 1% of patients had diarrhea, fatigue, and vomiting, respectively, among patients with AGIST after regorafenib treatment, which was given after failure with imatinib and sunitinib treatment.

4. Discussion

This study indicates that although no patients showed CR to regorafenib and had limited PFS (6.58 months), approximately 49% of patients with AGIST obtained CB (PR and SD) after regorafenib treatment, after the development of resistance to imatinib and sunitinib. Moreover, grade $\geq 3$ regorafenib-related adverse events, particularly hypertension, hand–foot skin reaction, and hypophosphatemia, should be noted in clinical practice. Secondary mutations in PDGFRA and KIT genes are the main mechanisms of resistance to imatinib and sunitinib.

The effect of regorafenib on AGISTs may occur through other signaling pathways in patients with resistance to imatinib and sunitinib. Apart from inhibiting KIT and PDGFR, regorafenib is an inhibitor of vascular endothelial growth factor (VEGF) receptors, tyrosine kinase with immunoglobulin and EGF
In conclusion, our results indicate that the effectiveness of regorafenib and patient survival need to be improved after failure with imatinib and sunitinib in patients with AGISTs. Moreover, close monitoring of potential grade ≥3 regorafenib-related adverse events, particularly hypertension, hand-foot skin reaction, and hypophosphatemia, should be performed during treatment.

References

[1] Mahvi DA, Keung EZ, Raut CP. Multimodality Therapy for Metastatic Gastrointestinal Stromal Tumor. 2017 Springer International Publishing.

[2] Soreide K, Sandvik OM, Soreide JA, et al. Global epidemiology of gastrointestinal stromal tumors (GIST): a systematic review of population-based cohort studies. Cancer Epidemiol 2016;40:39.

[3] Reichardt P, Demetri GD, Gelderblom H, et al. Correlation of KIT and PDGFRα mutational status with clinical benefit in patients with gastrointestinal stromal tumor treated with sunitinib in a worldwide treatment-use trial. BMC Cancer 2016;16:1-0.

[4] Martin-Broto J, Rubio L, Alemay R, et al. Clinical implications of KIT and PDGFRα in gastrointestinal stromal tumors. Cancer Chemother Rev 2011;6:209–20.

[5] Demetri GD, Cao VMM, Ad VDA, et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 2002;347:472–80.

[6] Blanke CD, Demetri GD, Mehren MV, et al. Long-term results from a randomized phase II trial of standard- versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT. J Clin Oncol 2008;26:6620.

[7] Heinrich MC, Ozvar K, Corless CL, et al. Correlation of kinase genotype and clinical outcome in the North American Intergroup Phase III Trial of imatinib mesylate for treatment of advanced gastrointestinal stromal tumors: CALGB 150105 Study by Cancer and Leukemia Group B and Southwest Oncology Group. J Clin Oncol 2008;26:5360–7.

[8] Lee JH, Kim Y, Choi JW, et al. Correlation of imatinib resistance with the mutational status of KIT and PDGFRα genes in gastrointestinal stromal tumors: a meta-analysis. J Gastrointest Liver Dis 2013;22:413.

[9] Demetri GD, Reichardt P, Kang YK, et al. Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet 2012;381:295–302.

[10] Yoon DH, Ryu MH, Ryoo BY, et al. Sunitinib as a second-line therapy for advanced GISTs after failure of imatinib: relationship between efficacy and tumor genotype in Korean patients. Invest New Drugs 2012;30:819.

[11] Joensuu H. Sunitinib for imatinib-resistant GIST. Lancet 2006;368:1303–4.

[12] Wang WL, Conley A, Reynoso D, et al. Mechanisms of resistance to imatinib and sunitinib in gastrointestinal stromal tumor. Cancer Chemother Pharmacol 2011;67:1–24.

[13] Daugherty MM, Heinrich MC. Regorafenib for treatment of imatinib- and sunitinib-resistant metastatic gastrointestinal stromal tumors. Expert Opin Orphan Drugs 2016;4:1–2.

[14] Kindler HL, Campbell NP, Wroblewski K, et al. Sorafenib (SOR) in patients (pts) with imatinib (IM) and sunitinib (SU)-resistant (RES) gastrointestinal stromal tumours (GIST): final results of a University of Chicago phase II consortium trial. J Clin Oncol 2011;29:10009.

[15] Lyseng-Williamson KA. Regorafenib: a guide to its use in advanced gastrointestinal stromal tumor (GIST) after failure of imatinib and sunitinib. BioDrugs 2015;27:523–31.

[16] Wilhelm SM, Dumas J, Adnane L, et al. Regorafenib (BAY 73-4506): a new oral multikinase inhibitor of angiogenic, stromal and oncocytic receptor tyrosine kinases with potent preclinical antitumor activity. Int J Cancer 2011;129:245.

[17] Kollár A, Maruzo M, Messiou C, et al. Regorafenib treatment for advanced, refractory gastrointestinal stromal tumor: a report of the UK managed access program. Clin Sarcoma Res 2014;4:17.

[18] George S, Wang Q, Heinrich MC, et al. Efficacy and safety of regorafenib in patients with metastatic and/or unresectable GI stromal tumor after failure of imatinib and sunitinib: a multicenter phase II trial. J Clin Oncol 2012;30:2401–7.

[19] Son MK, Ryu MH, Park JO, et al. Efficacy and Safety of Regorafenib in Korean Patients with Advanced Gastrointestinal Stromal Tumor After Failure of Imatinib and Sunitinib: A Multicenter Study Based on the Management Access Program. Gastrointestinal Cancers Symposium; 2015.

[20] Demetri GD, Reichardt P, Kang YK, et al. Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet 2013;381:295–302.

[21] Benami E, Barysawuska CM, Von MM, et al. Long-term follow-up results of the multicenter phase II trial of regorafenib in patients with metastatic and/or unresectable GI stromal tumor after failure of imatinib and sunitinib: clinical outcome. Oncology 2016;90:31.

[22] Wada N, Kurokawa Y, Takahashi T, et al. Detecting secondary C-KIT mutations in the peripheral blood of patients with imatinib-resistant gastrointestinal stromal tumor. Oncology 2016;90:12.

[23] Nishida T, Takahashi T, Nishitani A, et al. Sunitinib-resistant gastrointestinal stromal tumors harbor cis-mutations in the activation loop of the KIT gene. Int J Clin Oncol 2009;14:143–9.

[24] Zhao Y, Adjei AA. Targeting angiogenesis in cancer therapy: moving beyond vascular endothelial growth factor. Oncologist 2015;20:1–6.
[25] Reiss Y, Scholz A, Plate KH. The Angiopoietin–Tie System: Common Signaling Pathways for Angiogenesis, Cancer, and Inflammation. Springer, New York: 2015.

[26] Dao P, Jarray R, Smith N, et al. Inhibition of both focal adhesion kinase and fibroblast growth factor receptor 2 pathways induces anti-tumor and anti-angiogenic activities. Cancer Lett 2014;348:88–99.

[27] Basiliodeoliveira RP, Pannain VL. Prognostic angiogenic markers (endoglin, VEGF CD31) and tumor cell proliferation (Ki67) for gastrointestinal stromal tumors. World J Gastroenterol 2015;21: 6924–30.

[28] Nakayama T, Cho YC, Mine Y, et al. Expression of vascular endothelial growth factor and its receptors VEGFR-1 and 2 in gastrointestinal stromal tumors, leiomyomas and schwannomas. World J Gastroenterol 2006;12:6182–7.

[29] Wang Z, Xu J, Nie W, et al. Risk of hypertension with regorafenib in cancer patients: a systematic review and meta-analysis. Eur J Clin Pharmacol 2014;70:225–31.

[30] Robinson ES, Khankin EV, Karumanchi SA, et al. Hypertension induced by vascular endothelial growth factor signaling pathway inhibition: mechanisms and potential use as a biomarker. Semin Nephrol 2010;30:591–601.